Table 6 Treatment-emergent adverse events occurred at similar rates in patients using and not using migraine preventive treatments
TEAE | Lasmiditan dose (mg) | Using preventives | Not using preventives |
|---|---|---|---|
n/N (%) | n/N (%) | ||
Dizziness | PBO | 6/231 (2.6) | 31/1031 (3.0) |
All LTN | 81/544 (14.9) | 385/2633 (14.6) | |
Paresthesia | PBO | 2/231 (0.9) | 17/1031 (1.6) |
All LTN | 44/544 (8.1) | 136/2633 (5.2) | |
Somnolence | PBO | 5/231 (2.2) | 22/1031 (2.1) |
All LTN | 22/544 (4.0) | 153/2633 (5.8) | |
Fatigue | PBO | 2/231 (0.9) | 6/1031 (0.6) |
All LTN | 16/544 (2.9) | 104/2633 (3.9) | |
Nausea | PBO | 3/231 (1.3) | 17/1031 (1.6) |
All LTN | 21/544 (3.9) | 86/2633 (3.3) | |
Muscular Weakness | PBO | 0/231 (0.0) | 0/1031 (0.0) |
All LTN | 3/544 (0.6) | 39/2633 (1.5) | |
Hypoesthesia | PBO | 1/231 (0.4) | 2/1031 (0.2) |
All LTN | 3/544 (0.6) | 36/2633 (1.4) |